Skip to content
Biodatica
Start free

Tianjin Hemay Pharmaceutical Co., Ltd

Beijing

OncologyPhase III
Compare Sign in to watch

What changed

Phase III trial registered: A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

Apr 2025Trial registeredApr 22, 2025Source filing (opens the source filing in a new tab)

Momentum

40no change

Momentum 40 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Jan 8, 2022

    Breast Cancer · RECRUITING · sponsor: Tianjin Hemay Pharmaceutical Co., Ltd · A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

    ClinicalTrials.gov · NCT06313983 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources